Introduction:
Sofosbuvir is a non-structural protein 5B RNA-dependent RNA polymerase
inhibitor engineered for the treatment of chronic hepatitis C virus
(HCV) whose efficacy was established in subjects with HCV genotype 1, 2,
3 or 4 infections, including those with hepatocellular insufficiency and
with human immunodeficiency virus-1 co-infection (1). It is generally
well tolerated. Reported adverse events in sofosbuvir’s monograph are
usually not serious such as headache, nausea, insomnia, itching,
weakness, decreased appetite, chills, flu-like illness, joint pain, and
irritability. Vasculitis was rarely associated with sofosbuvir(2).
We report an exceptional case of a minor leucocytoclasic vasculitis with
a rapid favorable outcome after the drug withdrawal.